What is the first line treatment for primary generalized epilepsy

The retrieved studies do not answer what the first-line drug is for primary generalized epilepsy. They cover EEG patterns, heart function, memory, and case reports, but none is a modern treatment guideline or a head-to-head trial of first-line drugs in this population.

The evidence here is almost entirely off-topic. One 1994 trial compared valproate and carbamazepine in newly diagnosed adults, but it mixed partial and generalized seizures and was open-label, so the results are weak [4]. A 2015 study tested perampanel as an add-on in drug-resistant patients, not as a first-line drug [2]. A 1981 case report warns of fatal liver toxicity from high-dose valproate in a child, but that tells you about risk, not about first-line choice [1]. A 2012 review lists valproate, lamotrigine, and levetiracetam as suppressing photosensitivity, but that is a narrow lab endpoint, not a guideline for first-line treatment of all primary generalized epilepsies [3].

Outside this retrieval, the standard first-line drugs for primary generalized epilepsy are valproate, lamotrigine, and levetiracetam, with valproate historically considered most effective but carrying higher risks (birth defects, liver toxicity, weight gain). The choice depends on the patient's age, sex, and seizure type. But the retrieved studies do not provide the evidence to confirm or challenge that consensus. A proper answer would require a systematic review or a recent guideline, neither of which was captured here.

My call: the retrieval did not answer the question. The evidence to determine first-line treatment was not found. Confidence: not clear — the question is answerable from the literature, but this search missed it.